- November 1, 2017
- Integrated Biotherapeutics Inc. Partners with CARB-X the first Toxoid based Multivalent Vaccine for MRSA
CARB-X awards Integrated Biotherapeutics Inc. to develop a new breakthrough vaccine for the prevention of serious drug-resistant infections known as MRSA. The award commits funding in an initial period with the possibility of an increase based on the achievement of milestones to the satisfaction of CARB-X.
- ExpreS2ion enters multi-product agreement with US-based Integrated BioTherapeutics for expansion of their commercial reagents portfolio
Hørsholm, Denmark, July 17, 2017-ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a Master Services Agreement and a Research & Commercial License Agreement with the US based Integrated BioTherapeutics, Inc. (“IBT”). The agreements enable standardised activation of a range of services and products from ExpreS2ion. This primarily targets the development and manufacturing of proteins based on the ExpreS2 platform, as well as granting IBT commercial rights to promote, sell and distribute such protein products made with ExpreS2.
- Immunization-elicited Antibody Shows Universal Protection against Multiple Ebolaviruses
ROCKVILLE, Md., May 18, 2017 /PRNewswire/ -- In research published online today in Cell, a team of scientists describe an antibody called CA45, elicited by immunization of nonhuman primates (NHP) that binds to a region of the Ebola virus surface protein that is shared among all pathogenic ebolaviruses.
- IBT Receives Phase II STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses
IBT and Albert Einstein College of Medicine (EINSTEIN) receive a collaborative STTR grant from NIH, entitled Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease. A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. As the nature of future ebolavirus disease outbreaks cannot be predicted, development of broadly protective immunotherapeutics for ebolaviruses is urgently needed.
- IBT Receives a Partnership R01 grant from NIAID to Develop a Pan-Ebolavirus Vaccine
IBT and The Scripps Research Institute (TSRI) receive a collaborative Partnership R01 grant from NIH, entitled Rationally Designed Pan-Ebolavirus Vaccine. A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. Current experimental vaccines are strictly species-specific and do not provide broad protection against multiple ebolaviruses.
- IBT Receives NIH R01 grant to study the mechanisms of ebolavirus vaccine protection
IBT and University of Maryland receive a collaborative R01 research grant from NIH, Evolution of anti-filovirus B cell responses and mechanisms of protection.
- IBT Receives an SBIR from NIAID for development of a post-exposure vaccine for Streptococcus pneumoniae
IBT receives a SBIR grant from NIH, entitled Serotype independent therapeutic vaccine for Streptococcus pneumoniae. Antibiotic-resistant bacterial pathogens represent a major challenge within the community, healthcare settings, as well as the military. The growing incidence of bacterial pathogens signals the emergence of the so called “post-antibiotic era”. Vaccines exist only for Antibiotic-resistant bacterial pathogens. Innovative concepts are needed to face these serious challenges of the 21st century.
- Integral Molecular and Integrated BioTherapeutics Initiate Collaboration for Virus Vaccine Discovery
Integral Molecular and Integrated BioTherapeutics have teamed up in the fight against the global health crises posed by Ebola and Zika viruses, signing a collaborative vaccine discovery agreement to help eradicate these threats.
- International Society for Antiviral Research (ISAR) News Vol. 26 No.2
Javad Aman, the Chief Scientific Officer of Integrated BioTherapeutics Inc., is featured in the October 2016 Newsletter of the International Society for Antiviral Research (ISAR). Click to access the article and learn more about Javad’s career path and how he started the company.
- IBT Announces Licensing Agreement with Emergent BioSolutions for Development of Equine Immunoglobulin Therapeutics for Filovirus Infections
Integrated BioTherapeutics (IBT) announced today that it has entered into an exclusive worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS) whereby Emergent will gain exclusive rights to use IBT’s proprietary vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Financial terms of the agreement are not disclosed.
- July 18, 2016
- IBT Receives an SBIR from NIAID to engineer an Ebola Antibody to Achieve broad Filovirus Protection
Under this SBTR, IBT will work with Visterra, Inc. (Cambridge, MA) and US Army Medical Research Institute of Infectious Diseases (USAMRIID) to engineer a broadly reactive monoclonal antibody that only neutralizes ebolavirus species to achieve neutralizing activity towards Marburg virus.
- July 17, 2016
- IBT Receives an STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses
Under this STTR, IBT will work with Dr. Jon Lai at the Albert Einstein College of Medicine (AECOM) to generate a series of novel bispecific antibodies that target multiple broadly neutralizing epitopes in filovirus glycoprotein. A novel paradigm for fighting filovirus infections.
- April 26, 2016
- Progress Towards a Pan-Ebolavirus Treatment
This study is IBT's first step to demonstrating that ZMappTM can be modified and moved towards a broad reactivity.
- March 25, 2015
- IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
IBT scientists presented the new mAbs at the 7th International Symposium on Filoviruses held in Washington, DC.
- January 13, 2015
- Chembio Update on DPP(R) Ebola and DPP(R) Febrile Illness Assays
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP® Ebola and DPP® Febrile Illness Assays
- October 27, 2014
- Integrated BioTherapeutics Partners With Chembio
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases.
- July 2, 2014
- IBT Secures Another SBIR to Discover Staph Vaccines
NIAID has awarded the company a 2 year, $600,000 grant entitled "In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus."
- May 27, 2014
- Data Suggest IBT Investigational Ebola Vaccine Would Protect Wild Apes
The work represents the first time captive chimpanzees have been used for a trial that can benefit their own species rather than humans.
- June 10, 2013
- IBT and Stanford Awarded STTR
Integrated BioTherapeutics (IBT) and Stanford University have been jointly awarded a $300,000 Small Business Technology Transfer (STTR) grant.
- February 26, 2013
- New Bioterrorism Vaccine Gets First Test In Humans
Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults.
- August 22, 2012
- SBIR Award: Integrated BioTherapeutics
The company will receive nearly $600,000 for work to take place over the next two years under principal investigator Dr. M. Javad Aman, President and CSO of IBT.
- July 11, 2012
- SBIR Award: Integrated BioTherapeutics
Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH.
- June 13, 2012
- New Publication from the Researchers at IBT
Efforts to develop effective vaccines against Staphylococcus aureus (S. aureus) have been largely unsuccessful, in part due to the variety of virulence factors produced by this organism.